PAXIPEM

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Feb 9, 2023 → Oct 25, 2026

Cited window

Feb 9, 2023 → Jul 17, 2025

Retrieved

Oct 31, 2026

Title

Multicenter Phase II Study of Axitinib +/- Pembrolizumab in First Line Treatment for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Registry

NCT05096390

Study IDs

PAXIPEM (ET21-023) · ET21-023 (Centre Leon Berard)

Sponsor

Centre Leon Berard

Design

Phase 2 · Interventional, randomized, parallel

Status

Unknown

Enrollment

72 estimated

Registered

2021-10-27

Start

2022-06-01 actual

Primary completion

2024-10 estimated

Primary endpoint

Efficacy of axitinib + pembrolizumab versus axitinib in patients with locally advanced or metastatic type 2 papillary renal carcinoma in first-line treatment.

Interventions

2 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Not yet captured in this edition: a view on biomarker-selected checkpoint and targeted combination therapy in advanced papillary kidney cancer, with small-study uncertainty.
• –Not yet captured in this edition: a remark on patient-facing trial-finding tools supporting access to papillary kidney cancer research.
• –Not yet captured in this edition: a view on uncertainty over appropriate control arms for systemic-treatment trials in advanced papillary renal cell carcinoma.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –128 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The sources reviewed for this edition contain no PAXIPEM outcome data or exact-trial results publication. No separate protocol document or exact product-label documents for either trial drug were available; registry descriptions are planned methods, not observed efficacy or safety.
• –Several podcast editions reproduce the same panel, and social posts were reposted. Source totals cannot be interpreted as numbers of independent HCPs, endorsements or a measure of consensus.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –Many statements concern metastatic papillary or broader non-clear-cell RCC. Approximate cross-histology figures and preferences for alternative regimens are not type 2 papillary-specific estimates or PAXIPEM comparative findings.
• –Regulatory history, reimbursement experience, guideline-access expectations, future practice impact and biological-development forecasts remain the speakers' recollections, interpretations or hopes.
• –Publication and post dates do not establish trial readout dates, session timing or changes of mind across settings.
• –This report does not detail organization-specific trial-navigation resources or proposals linking molecular and biobank data with institutional treatment experience, including AI-enabled analysis. Its account of participation support and translational strategy is therefore incomplete.

How reports are built and checked: Methods.

Last checked for new commentary Oct 31, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "PAXIPEM" (NCT05096390), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "paxipem-05096390". If you cannot make requests, read https://www.erudio.com/reports/paxipem-nct05096390.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT05096390", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct05096390 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/paxipem-nct05096390.json
curl https://www.erudio.com/reports/paxipem-nct05096390.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "paxipem-05096390" })